Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Kenneth Cusi, Naim Alkhouri, Stephen A. Harrison, Pascale Fouqueray, David E. Moller, Sophie Hallakou‐Bozec, Sébastien Bolze, Jean‐Marie Grouin, S. Megnien, Julie Dubourg, Vlad Ratziu
Topics & Concepts
MedicineClinical endpointInternal medicinePlaceboFatty liverPopulationGastroenterologyClinical trialDiseasePathologyAlternative medicineEnvironmental healthMetabolism, Diabetes, and CancerLiver Disease Diagnosis and TreatmentDiet and metabolism studies